Clinical trials: Cancer of Nasopharynx
Nasopharyngeal Carcinoma
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant therapy of locoregionally advanced nasopharyngeal…
- Trial name
- NCT05211232
- Testing
- Tislelizumab
- Where
- 4 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Oral Complications of Radiation Therapy
CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy
RATIONALE: Lactobacillus bevis CD2 lozenge may help prevent symptoms of mucositis, or mouth sores, in patients receiving radiation therapy and chemotherapy.
- Conditions
- Head and Neck Cancer, Oral Complications of Radiation Therapy, Pain, Weight Changes
- Trial name
- NCT01545687
- Testing
- Lactobacillus brevis CD2 lozenge
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced Head and Neck Squamous Cell Carcinoma
the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer
This study is to observe and compare the effect of docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy and TPF induction chemotherapy combined with cisplatin chemoradiotherapy on dendritic…
- Trial name
- NCT03196869
- Testing
- Chrono-chemotherapy, Routine intravenous drip, induction Chrono-chemotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Guiyang Medical University
Locally Recurrent Cancer, Metastatic Nasopharyngeal Cancer
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- 2018/00947 (NCT03813394)
- Testing
- pembrolizumab, bevacizumab
- Where
- Singapore
- Volunteers
- 48 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer
The purpose of this study is to investigate whether reducing both the dose and the irradiated volume of cervical prophylactic irradiation in patients with nasopharyngeal cancer can maintain efficacy while decreasing toxicity.
- Trial name
- NCT06775756
- Testing
- IMRT with reduced-dose and reduced-volume cervical prophylactic irradiation
- Volunteers
- 474 people
- Sponsor
- Fujian Cancer Hospital
Head and Neck Cancer, Oral Complications of Radiation Therapy
Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Iseganan hydrochloride may be effective in preventing or lessening oral mucositis in patients who are receiving radiation therapy for head and neck cancer.
- Conditions
- Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
- Trial name
- NCT00022373
- Testing
- iseganan HCl oral solution, management of therapy complications
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer.
- Conditions
- EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7
- Trial name
- NCT02135042
- Testing
- Bone Scan, Cisplatin, Clinical Observation
- Where
- 213 sites in United States, Australia and 6 more
- Volunteers
- 924 people
- Sponsor
- NRG Oncology
Nasopharyngeal Carcinoma
A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Locoregionally advanced nasopharyngeal carcinoma (NPC)(stage III, IV in UICC 2002 Classification) can be divided into two groups according to the risk of metastasis: high-risk metastasis group (T4 or N2-3) and low-risk metastasis…
- Trial name
- NCT00705627
- Testing
- neoadjuvant chemotherapy plus concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
This trial intends to enroll patients with T4N1 or T1-4N2-3 (AJCC 8th) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT04870905
- Testing
- Tis-U-Sol
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Head and Neck Cancer
Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent or…
- Trial name
- NCT00006471
- Testing
- Fenretinide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available
- Trial name
- NCT04925544
- Testing
- VK-2019
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Nasopharyngeal Carcinoma (NPC)
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07064902
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer
Hypothesis: To estimate the proportion of locally advanced, recurrent or metastatic nasopharyngeal cancer patients which show high somatostatin receptor density (SUVmax >10) on Ga-68 DOTATATE imaging.
- Trial name
- NCT03670342
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National Cancer Centre, Singapore
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic…
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
- Trial name
- NCT07824856
- Testing
- CT-guided percutaneous local ablation, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines
Currently, nasopharyngeal carcinoma (NPC) patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II will be recommended to receive…
- Trial name
- NCT05519956
- Testing
- level Ib-covering IMRT, level Ib-sparing IMRT
- Volunteers
- 398 people
- Sponsor
- Fujian Cancer Hospital
Mucositis, Oral Complications
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
This randomized pilot clinical trial studies whether acetylcysteine oral rinse will lessen saliva thickness and painful mouth sores in patients with head and neck cancer undergoing radiation therapy.
- Conditions
- Mucositis, Oral Complications, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
- Trial name
- NCT02123511
- Testing
- acetylcysteine, quality-of-life assessment, questionnaire administration
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Nasopharyngeal Carcinoma by AJCC V8 Stage
NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma
This is a prospective, single-center clinical trial in eccentric nasopharyngeal carcinoma (NPC) patients. The aim of this study is to evaluate the efficacy and safety of NBI combined with MRI-guided optimized CTV compared with…
- Trial name
- NCT06167109
- Testing
- CTV optimized IMRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing University Cancer Hospital
Malnutrition, Nasopharyngeal Carcinoma
Early Nutritional Intervention in NPC Patients Undergoing Concurrent Chemoradiotherapy
This single center, open-label, randomized controlled clinical trial was designed to investigate whether early nutritional intervention with oral nutrition supplements in patients with nasopharyngeal carcinoma undergoing…
- Trial name
- NCT04810936
- Testing
- oral nutritional supplements
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Guangdong Provincial People's Hospital
Nasopharyngeal Carcinoma, PD-1
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of…
- Conditions
- Nasopharyngeal Carcinoma, PD-1, Surgery
- Trial name
- NCT04778956
- Testing
- Toripalimab, salvage surgery
- Where
- 7 sites in China
- Volunteers
- 218 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04437329
- Testing
- Docetaxel, nedaplatin, fluorouracil, Docetaxel, cisplatin, fluorouracil, Nedaplatin
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.